Children's Art Project at The University of Texas MD Anderson Cancer Center

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

Retrieved on: 
Monday, November 6, 2023
Neoplasm, PVRL2, Ovarian cancer, Nivolumab, TIGIT, Pembrolizumab, Compugen, Telephone, Children's Art Project at The University of Texas MD Anderson Cancer Center, PD-1, Data, SITC, Immunotherapy, MD Anderson Cancer Center, Biology, Breast cancer, Annual general meeting, Platinum, TASE, Tumor microenvironment, University, Safety, Society, Patient, Birth control, Medical imaging, PVRIG

The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.

Key Points: 
  • The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.
  • "We were delighted to present at SITC clinical data which reinforces data previously presented, suggesting that COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy", said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • In addition, we presented data in metastatic breast cancer, another indication in which patients who typically do not respond to immunotherapy, derived clinical benefit from COM701 combinations."
  • I look forward to the results of the ongoing proof-of-concept study evaluating the combination of COM701, COM902 and pembrolizumab in platinum resistant ovarian cancer patients."

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Retrieved on: 
Wednesday, September 20, 2023
Mohamed Jazaeri, GSK, OCCC, Obstetrics, Children's Art Project at The University of Texas MD Anderson Cancer Center, Survival, Clinical trial, Gynecologic Oncology (journal), DRS, Monroe Dunaway Anderson, Immunotherapy, Feinberg School of Medicine, Assistant, Squamous-cell carcinoma, Patient, Anderson, University, Gynaecology, Observation, PD-1, MPH, MD Anderson Cancer Center, Clinical, Northwestern, Pharmaceutical industry, PP2A, John Hinchcliff, MD

PASADENA, CA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), today announced a Phase 1b collaborative clinical trial to assess whether adding Lixte’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will be conducted at MD Anderson and will also be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center. LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.

Key Points: 
  • The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will be conducted at MD Anderson and will also be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.
  • The clinical trial is based on the observation of longer survival of patients with OCCC treated with immunotherapy whose cancer cells have an acquired gene mutation resulting in a reduction in PP2A.
  • This clinical trial is an exciting alternative approach that leverages the potential synergy between these two agents and is aiming to improve the impact immunotherapy may have for these patients.”

Negative reinforcement? FTC proposes amending Negative Option Rule to include click-to-cancel and other protections

Retrieved on: 
Monday, July 24, 2023
Online, People, Comcast, Deception, Match Group, Federal Trade Commission Act of 1914, Industry, Food, Rule, Failure, Register, Method, Federal Trade Commission, Catalog, Commission, PayPal, Eye, Policy, Record, ROSCA, Children's Art Project at The University of Texas MD Anderson Cancer Center, Attention, Blog, Privacy, Match.com, Holiday, Walking, Federal Register, Notice, Social Security, Time, FTC, Comment, Frustration, Cell, Verizon Communications, Social, Fraud, T-Mobile, HelloFresh, Mail, Cryptocurrency, Online shopping, Risk management, Book

Negative reinforcement? FTC proposes amending Negative Option Rule to include click-to-cancel and other protectionsBut as decades of FTC law enforcement makes clear, when negative options are tainted with untruths, half-truths, and hidden strings, the impact on consumers can be, well, negative.

Key Points: 

Negative reinforcement? FTC proposes amending Negative Option Rule to include click-to-cancel and other protections

    • But as decades of FTC law enforcement makes clear, when negative options are tainted with untruths, half-truths, and hidden strings, the impact on consumers can be, well, negative.
    • That’s why the FTC is asking for public comment on proposed amendments to its Negative Option Rule designed to combat unfairness and deception.
    • However, the current Negative Option Rule applies only to prenotification plans, an older (and frankly, fading) business model.
    • Given the narrow scope of the existing Negative Option Rule, the time seems right for a rethink.
    • A second reason why the FTC is asking for your feedback about proposed changes to the Rule is because problematic negative option practices continue to inflict consumer injury.

Drawing, making music and writing poetry can support healing and bring more humanity to health care in US hospitals

Retrieved on: 
Saturday, June 10, 2023
People, Blood pressure, Exercise, Medicine, Children's Art Project at The University of Texas MD Anderson Cancer Center, Optimism, Depression, Life, Poetry, Internal medicine, Hospital, Anxiety, Parent, Stroke, COVID-19, Hope, Research, Monroe Dunaway Anderson, Emotion, Goal, Language, Creativity, Pain, Patient, Time, Diagnosis, Mortality, Efficiency, Empathy, System, Campo, Death, Mental health, Nursing, Pharmaceutical industry, Health insurance, Medical imaging

Having relatives peering through windows at their loved ones or unable to enter hospitals altogether exacerbated the lack of human intimacy that is all too common in health care settings.

Key Points: 
  • Having relatives peering through windows at their loved ones or unable to enter hospitals altogether exacerbated the lack of human intimacy that is all too common in health care settings.
  • Opportunities for creative expression through arts in medicine programs are increasing in U.S. hospitals, and it may be because art-making offers something that medicine can’t.
  • Research has also shown that these programs can bring relief from the stresses and burnout that health care workers regularly experience.
  • Arts in medicine programs are also correlated with improved blood pressure and less pain and depression for some patients.

Art therapy reduces the sense of isolation

    • Ian Cion founded the hospital’s arts in medicine program in 2010.
    • Cion’s goal with such collaborative projects was to pull people out of the isolation of illness and into community, and to celebrate and embrace the unknown.

Detachment and routine are rife in hospital settings

    • Some were licensed mental health professionals who were professionally prepared for such work, such as art therapists, music therapists and poetry therapists.
    • People experiencing hospitalization have shared with me that they often don’t feel seen for who they are when they enter the hospital setting.
    • One gentleman stated that he felt literally stripped of his social identity when he was asked to don the anonymous hospital gown.
    • But when artists enter the hospital room, they recognize patients as whole people, apart from their diagnosis.

Embracing uncertainty

    • But my research shows that art-making also provides an important opportunity to engage with the unknown.
    • In medicine, the focus is typically on imaging and other testing to reach a diagnosis and a course of treatment.

Building trust through poetry

    • I, like some of Campo’s colleagues, wondered how there was room for poetry in the very short time doctors get to spend with their patients.
    • Rather than taking up time, the use of poetry builds trust so that patients share their deepest worries more quickly, he noted, giving him more time to meaningfully address them.

The need for a new language around loss and death

    • Nearly everyone will face a point in their lives where medicine cannot provide a solution or sustain life.
    • Our cultural and medical narratives of illness often do not have adequate language for these moments.
    • She told me about a mother who created collages of her very worst fears as well as what brought her hope and strength.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

Mission Bio partners with global pharma and academic institutions to demonstrate Tapestri® Platform's translational utility for precision therapeutics at ASH

Retrieved on: 
Wednesday, December 7, 2022
Multiomics, Therapy, Exposition, B cell, Measure (mathematics), Ernest, Assay, Azacitidine, Single cell, Society, Patient, DNA, Cancer, Agilent Technologies, MSK, Memorial Sloan Kettering Cancer Center, HIV disease progression rates, Tablet, AML, CAR, Booth, University, Children's Art Project at The University of Texas MD Anderson Cancer Center, Health, MRD, ASH, Mayfield (company), Pharmaceutical industry, Franses Tapestry Archive, Laboratoires Servier

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and multiple biopharma and academic partners are presenting data from the company's Tapestri® Platform on a range of topics at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, beginning this weekend in New Orleans, LA. In all, Mission Bio and its partners will share 15 heme-oncology topics highlighting the use of single-cell DNA + protein multi-omics to better understand resistance mechanisms and drivers of relapse, improve identification of Measurable Residual Disease (MRD), and precisely characterize CAR T cell therapies.  These include presentations from Servier Pharmaceuticals and researchers at Memorial Sloan Kettering Cancer Center (MSK) that demonstrate Tapestri's® ability to bridge the gap between translational research and precision therapeutics, providing a deeper understanding of the patient journey and unlocking novel therapeutic approaches. These include the following:

Key Points: 
  • Researchers identified potential mechanisms of acquired resistance in patients with IDH1-mutated acute myeloid leukemia (AML) using single-cell DNA sequencing with Tapestri.
  • "Mission Bio has led the way into a new era for precision therapeutics with single-cell DNA + protein multi-omics," said Todd Druley, Chief Medical Officer at Mission Bio.
  • Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health.
  • Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution.

Tiff's Treats Opens Warm Cookie Delivery Location in Pearland, Texas, Marking 16th Houston-Area Store

Retrieved on: 
Monday, April 18, 2022
Month, Family, Brain, University, Connor, Pearland Town Center, Tiffany, Organic, Children's Art Project at The University of Texas MD Anderson Cancer Center, Hospital, Treats, Survival rate, Sienna, Texas, Diffuse intrinsic pontine glioma, Mobile, DIPG, Broadway, Time, Baking, Tiff

AUSTIN, Texas, April 18, 2022 /PRNewswire-PRWeb/ -- Tiff's Treats, the direct-to-consumer, on-demand delivery brand that invented the concept of baked-to-order warm cookie delivery, has opened a new Houston-area location in the Pearland Town Center at 11200 Broadway Street #410.

Key Points: 
  • AUSTIN, Texas, April 18, 2022 /PRNewswire-PRWeb/ -- Tiff's Treats, the direct-to-consumer, on-demand delivery brand that invented the concept of baked-to-order warm cookie delivery , has opened a new Houston-area location in the Pearland Town Center at 11200 Broadway Street #410.
  • A $5 ticket scores each guest a dozen warm, freshly baked cookies in Tiff's Treats' most popular flavors, chocolate chip and snickerdoodle.
  • Tiff's Treats' Pearland store is now open with a full menu of classic cookies and treats available for warm, fresh delivery or in-store pickup.
  • As an apology, she baked and delivered a batch of warm cookies, and the concept of warm cookie delivery was born.

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

Retrieved on: 
Thursday, February 17, 2022
Myelodysplastic syndrome, Roche, Patient, Global Monitoring Plan, Cancer, LSU, Tumor necrosis factor, Human, MDS, Toxic epidermal necrolysis, CD47, Neoplasm, KAHR, Acute myeloid leukemia, Tumor microenvironment, Clinical trial, LP, Safety, Venetoclax, Therapy, University, MD, Children's Art Project at The University of Texas MD Anderson Cancer Center, Monroe Dunaway Anderson, MD Anderson Cancer Center, Partnership, Anderson, Pharmacokinetics, Lymphatic system, Research, Palestinian National Interest Committee, AML, Azacitidine, Macrophage, Pharmaceutical industry, Vaccine, Leukemia

The clinical trial is being funded by a previously announced investment from Cancer Focus Fund.

Key Points: 
  • The clinical trial is being funded by a previously announced investment from Cancer Focus Fund.
  • "This trial in challenging blood cancers complements our ongoing Phase 1/2 clinical trial in patients with advanced solid tumors.
  • DSP107 is in a Phase 1/2 clinical trial for solid tumor cancers and a Phase 1b trial for blood cancers.
  • DSP107 is being tested in a Phase 1b clinical trial in blood cancers and a Phase1/2 clinical trial in advanced solid tumors.